Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.95
+1.84 (15.19%)
Jun 15, 2026, 11:33 AM EDT - Market open

Intellia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,9491,0461,1902,8353,0398,807
Market Cap Growth
152.58%-12.10%-58.04%-6.70%-65.49%144.43%
Enterprise Value
1,434689.14798.352,0391,9778,133
Last Close Price
13.958.9911.6630.4934.89118.24
PS Ratio
28.3115.4520.5678.1758.31266.46
PB Ratio
2.351.561.362.702.468.47
P/TBV Ratio
2.521.451.322.582.178.06
EV/Sales Ratio
21.7010.1813.7956.2037.93246.05
Debt / Equity Ratio
0.100.100.220.090.090.06
Net Debt / Equity Ratio
-0.48-0.53-0.45-0.76-0.86-0.65
Net Debt / EBITDA Ratio
0.720.830.751.572.362.59
Net Debt / FCF Ratio
0.810.901.101.953.062.84
Asset Turnover
0.080.070.050.030.040.03
Quick Ratio
5.044.425.508.239.455.97
Current Ratio
6.105.085.778.679.616.11
Return on Equity (ROE)
-61.07%-53.48%-54.00%-42.10%-41.67%-34.18%
Return on Assets (ROA)
-52.56%-43.38%-42.88%-36.53%-32.56%-27.18%
Return on Invested Capital (ROIC)
-124.79%-93.80%-114.23%-145.72%-95.27%-78.08%
Return on Capital Employed (ROCE)
-59.23%-48.50%-47.16%-39.96%-35.76%-30.08%
Buyback Yield / Dilution
-11.18%-9.64%-11.35%-15.33%-8.57%-26.63%
Total Shareholder Return
-11.18%-9.64%-11.35%-15.33%-8.57%-26.63%
SEC Filings: 10-K · 10-Q